Table 3.
Summary results of the subgroup analysis.
| Variables | Item | Standard | No. of Trials | I2(%) | WMD (95 % CI) | P |
|---|---|---|---|---|---|---|
| SBP | dose | >300 mg | 4 | 50.3 | −2.60 (−6.18,0.99) | 0.213 |
| ≦300 mg | 4 | 27.6 | −1.50 (−3.87,0.87) | 0.156 | ||
| Duration | ≧12weeks | 7 | 0.0 | −1.04 (−3.14,1.06) | 0.332 | |
| <12weeks | 1 | – | −8.00 (−13.84,-2.16) | 0.007 | ||
| Health status | Health | 6 | 27.0 | −1.36 (−3.62,0.91) | 0.241 | |
| Disease | 2 | 65.0 | −3.36 (−7.39,0.68) | 0.103 | ||
| Weight management | Yes | 5 | 10.5 | −1.37 (−3.80,1.06) | 0.271 | |
| No | 3 | 63.8 | −2.75 (−6.15,0.64) | 0.112 | ||
| DBP | dose | >300 mg | 4 | 74.6 | −0.27 (−4.92,4.38) | 0.910 |
| ≦300 mg | 4 | 43.0 | −3.05 (−5.52,-0.59) | 0.015 | ||
| Duration | ≧12weeks | 7 | 68.5 | −0.83 (−3.64,1.97) | 0.56 | |
| <12weeks | 1 | – | −6.00 (−9.52,-2.48) | 0.001 | ||
| Health status | Health | 6 | 52.6 | −1.28 (−4.02,1.46) | 0.359 | |
| Disease | 2 | 82.1 | −1.99 (−8.87,4.88) | 0.570 | ||
| Weight management | Yes | 3 | 36.8 | −3.51 (−6.60,-0.42) | 0.026 | |
| No | 5 | 78.0 | −0.27 (−4.21,3.67) | 0.892 | ||
| TC |
dose | >300 mg | 5 | 50.2 | 0.09 (−0.15,0.33) | 0.447 |
| ≦300 mg | 5 | 43.6 | −0.46 (−0.73,-0.19) | 0.001 | ||
| Duration | ≧12weeks | 8 | 59.6 | −0.28 (−0.53,-0.04) | 0.024 | |
| <12weeks | 2 | 70.1 | 0.17 (−0.27,0.60) | 0.458 | ||
| Health status | Health | 7 | 76.5 | −0.19 (−0.50,0.11) | 0.212 | |
| Disease | 3 | 75.4 | −0.18 (−0.70,0.35) | 0.514 | ||
| Weight management |
Yes |
3 |
85.9 |
−0.04 (−0.50,0.42) |
0.871 |
|
| Variables |
Item |
Standard |
No. of Trials |
I2(%) |
WMD (95 % CI) |
P |
| TC | Weight management | No | 7 | 62.8 | −0.27 (−0.57,0.03) | 0.078 |
| TG | dose | >300 mg | 5 | 72.2 | −0.03 (−0.31,0.25) | 0.839 |
| ≦300 mg | 6 | 0.0 | −0.32 (−0.46,-0.19) | 0.000 | ||
| Duration | ≧12weeks | 9 | 60.5 | −0.20 (−0.40,-0.01) | 0.044 | |
| <12weeks | 2 | 82.1 | −0.11 (−0.53,0.30) | 0.587 | ||
| Health status | Health | 8 | 62.3 | −0.21 (−0.41,-0.01) | 0.044 | |
| Disease | 3 | 72.6 | −0.12 (−0.49，0.26) | 0.545 | ||
| Weight management | Yes | 4 | 0.0 | −0.24 (−0.40，-0.09) | 0.002 | |
| No | 7 | 75.1 | −0.15 (−0.42，0.11) | 0.251 | ||
| LDL | dose | >300 mg | 5 | 19.0 | 0.041 (−0.11，0.19) | 0.592 |
| ≦300 mg | 5 | 37.8 | −0.34 (−0.59，-0.09) | 0.008 | ||
| Duration | ≧12weeks | 8 | 47.9 | −0.18 (−0.38，0.02) | 0.071 | |
| <12weeks | 2 | 63.0 | −0.13 (−0.30，0.04) | 0.958 | ||
| Health status | Health | 7 | 56.4 | −0.12 (−0.32，0.08) | 0.257 | |
| Disease | 3 | 66.6 | −0.19 (−0.59，0.21) | 0.361 | ||
| Weight management | Yes | 3 | 63.8 | −0.03 (−0.29，0.22) | 0.804 | |
| No | 7 | 50.0 | −0.20 (−0.43，0.03) | 0.087 | ||
| HDL | dose | >300 mg | 5 | 82.3 | 0.09 (−0.05，0.23) | 0.188 |
| ≦300 mg | 6 | 0.0 | 0.06 (−0.00，0.11) | 0.052 | ||
| Duration | ≧12weeks | 9 | 0.0 | 0.03 (−0.01，0.08) | 0.131 | |
| <12weeks | 2 | 88.6 | 0.24 (−0.06，0.55) | 0.116 | ||
| Health status | Health | 8 | 72.7 | 0.08 (−0.02，0.17) | 0.107 | |
| Disease | 3 | 0.0 | 0.07 (−0.01，0.15) | 0.084 | ||
| Weight management | Yes | 4 | 85.2 | 0.12 (−0.06，0.31) | 0.186 | |
| No | 7 | 0.0 | 0.05 (−0.01，0.10) | 0.082 |